MRD Monitoring in MDS Patients (with Prof Arjan van de Loosdrecht)

Join host Professor Kirsten Gronbaek and guest Professor Arjan van de Loosdrecht as they dive into the complexities of measurable residual disease (MRD) monitoring in myelodysplastic syndromes (MDS) and myeloid cancers. Professor van de Loosdrecht explains the transition from minimal to measurable residual disease, the significance of MRD in predicting disease outcomes, and the various techniques used for MRD detection.   Listen as they explore the challenges and potential strategies for MRD monitoring in MDS, and the implications for treatment decisions. This episode is a must-listen for anyone interested in the latest advancements in hematology and the future of MRD monitoring in MDS.  Tune in to EHA Unplugged to gain valuable insights and stay updated with the latest research and clinical practices in hematology.Host: Prof Kirsten GronbaekGuest: Prof Arjan van de LoosdrechtLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: [email protected] to receive the EHA Educational Updates via https://eha.news/subscribe 

There are no comments yet.

Please log in to write the first comment.